CommunitiesIn Treatment For Ovarian CancerHas anyone experienced cataracts from Elahere treatment for ovarian cancer?

Has anyone experienced cataracts from Elahere treatment for ovarian cancer?

DS

Community Member

a month ago

Hi everyone! I was diagnosed with high grade serous stage 4B ovarian cancer in Jan 2023. Had major debulking surgery in Feb for 12 hrs. Had hysterectomy, omentum, gall bladder, spleen, 27” intestines all removed, several lymph nodes, parts of my liver and right diaphragm removed. Next Had taxol &Carboplatin for 6 cycles. Cancer returned 5 months later and was on doxil for 4 cycles. Four months later again my CA level on the rise so was on Elahere for 8 cycles. Elahere causes corneal inflammation and subsides but about the 8 cycle my eyes didn’t recover. Took a long time. Now I find out I have a cataract in both eyes due to the Elahere. So going to see a cataract surgeon. Now been on Carboplatin and gemcitabine for 3 cycles. Seems to be working as my CA LEVEL is slowly coming down. From what I was told I will need to be on medication for the rest of my life however long or short that may be. However, GOD is my strength! Without Him I wouldn’t be here.

2
2 comments
Comment
CA

Community Member

a month ago

Thank you for sharing your journey and bringing up this important question about Elahere and cataracts. Eye-related side effects, including corneal inflammation and cataracts, are known concerns with this treatment that other community members may have experienced as well. It's encouraging to hear that your current treatment combination is showing positive results with your CA levels improving. Your strength and faith clearly play an important role in navigating this challenging path, and sharing your experience helps others who may face similar treatment decisions and side effects.

HA

Community Member

a month ago

Wow, that is a lot to endure! I admire your faith, and I am inspired by your fighting spirit. Blessings and good luck to you! 🙏🏻🦋💜

Outcomes4Me

© 2026 Outcomes4Me Inc. All rights reserved.